AUTHOR=Cognasse Fabrice , Hamzeh-Cognasse Hind , Duchez Anne-Claire , Shurko Natalia , Eyraud Marie-Ange , Arthaud Charles-Antoine , Prier Amélie , Heestermans Marco , Hequet Olivier , Bonneaudeau Brigitte , Rochette-Eribon Sandrine , Teyssier Françoise , Barlet-Excoffier Valérie , Chavarin Patricia , Legrand Dominique , Richard Pascale , Morel Pascal , Mooney Nuala , Tiberghien Pierre TITLE=Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology JOURNAL=Frontiers in Immunology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1034379 DOI=10.3389/fimmu.2022.1034379 ISSN=1664-3224 ABSTRACT=
Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if administered early in the disease, particularly in patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms. This study examined the influence of photochemical Pathogen Reduction Treatment (PRT) using amotosalen‐HCl and UVA light in comparison with untreated control convalescent plasma (n= 72 – paired samples) - cFFP, regarding soluble inflammatory factors: sCD40L, IFN-alpha, IFN-beta, IFN-gamma, IL-1 beta, IL-6, IL-8, IL-10, IL-18, TNF-alpha and